Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations

Table 2 Baseline characteristics of our participants who had magnetic resonance imaging scans compared to index study participants who did not have magnetic resonance imaging scans

Characteristic	Non-MRI scan group (n = 49)	MRI scan group (n = 39)	P value
Age, yr	62 (58-68)	62 (58-67)	0.6
Duration of type 2 diabetes, yr	9 (4-12)	8 (5-11)	> 0.9
Insulin therapy, n (%)	13 (26.5)	5 (12.8)	0.19
Weight, kg	102 (89-111)	95 (90-104)	0.12
BMI, kg/m2	33.4 (31.2-35.9)	31.5 (28.2-35.3)	0.012
Waist circumference, cm	116 (109-123)	111 (104-118)	0.024
Fat mass, g	32696 (29299-39109)	31832 (26820-37809)	0.2
Lean mass, g	62004 (58056-66170)	60,049 (54278-64848)	0.12
ALT, IU/L	34 (25-50)	32 (25-42)	0.7
ALP, IU/L	71 (56-82)	66 (54-75)	0.2
GGT, IU/L	30 (24-43)	32 (24-43)	0.8
TT, nmol/L (ECLIA)	8.5 (7.3-10.5)	8.1 (6.7-11.4)	0.8
cFT, pmol/L (ECLIA)	176 (151-230)	194 (148-253)	0.6
SHBG, nmol/L	28 (24-32)	29 (22-34)	> 0.9
LH, IU/L	4.5 (3.5-6.2)	4.5 (3.4-6.4)	0.9
Fasting glucose, mmol/L	8.2 (7.0-10.6)	8.6 (7.3-9.9)	> 0.9
HbA1c, %	7.1 (6.6-7.7)	6.9 (6.5-7.3)	0.4
Cholesterol, mmol/L	4.1 (3.5-4.7)	4.6 (4.0-4.9)	0.005
LDL, mmol/L	2.0 (1.6-2.4)	2.7 (2.0-3.1)	< 0.001
HDL, mmol/L	1.0 (0.9-1.2)	1.1 (0.9-1.2)	0.5
SAT, cm3	4095 (3526-5593)	4661 (3137-5385)	0.7
VAT, cm3	4786 (3,642-5,617)	3634 (2780-4823)	0.044

Data are median (IQR). MRI: Magnetic resonance imaging; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TT: Total testosterone; cFT: Calculated free testosterone; SHBG: Sex hormone-binding globulin; LH: Luteinising hormone; LDL: Low-density lipoprotein; HDL: High density lipoprotein; SAT: Subcutaneous adipose tissue; VAT: Visceral adipose tissue.